MedTrace Logo

Study of Oral Dehydroepiandrosterone(DHEA) to Treat Previously Unexplained Infertility

NCT00650754 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2015-09-30

No results posted yet for this study

Summary

The experimental focus of this project is on the interaction of DHEA treatment on pregnancy in women with otherwise unexplained infertility and evidence of premature ovarian aging (POA).

Conditions

  • Primary Ovarian Insufficiency
  • Unexplained Infertility

Interventions

DIETARY_SUPPLEMENT

Dehydroepiandrosterone

25 mg PO TID

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Center for Human Reproduction

    lead OTHER

Principal Investigators

  • David Barad, MD, MS · Center for Human Reproduction

  • Norbert Gleicher, MD · Center for Human Reproduction

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
21 Years
Max Age
37 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-03-31
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00650754 on ClinicalTrials.gov